Literature DB >> 26537124

Acute disruption of glucagon secretion or action does not improve glucose tolerance in an insulin-deficient mouse model of diabetes.

Vivi R Steenberg1, Signe M Jensen1, Jens Pedersen1, Andreas N Madsen2, Johanne A Windeløv1, Birgitte Holst2, Bjørn Quistorff1, Steen S Poulsen1, Jens J Holst3.   

Abstract

AIMS/HYPOTHESIS: Normal glucose metabolism depends on pancreatic secretion of insulin and glucagon. The bihormonal hypothesis states that while lack of insulin leads to glucose underutilisation, glucagon excess is the principal factor in diabetic glucose overproduction. A recent study reported that streptozotocin-treated glucagon receptor knockout mice have normal glucose tolerance. We investigated the impact of acute disruption of glucagon secretin or action in a mouse model of severe diabetes by three different approaches: (1) alpha cell elimination; (2) glucagon immunoneutralisation; and (3) glucagon receptor antagonism, in order to evaluate the effect of these on glucose tolerance.
METHODS: Severe diabetes was induced in transgenic and wild-type mice by streptozotocin. Glucose metabolism was investigated using OGTT in transgenic mice with the human diphtheria toxin receptor expressed in proglucagon producing cells allowing for diphtheria toxin (DT)-induced alpha cell ablation and in mice treated with either a specific high affinity glucagon antibody or a specific glucagon receptor antagonist.
RESULTS: Near-total alpha cell elimination was induced in transgenic mice upon DT administration and resulted in a massive decrease in pancreatic glucagon content. Oral glucose tolerance in diabetic mice was neither affected by glucagon immunoneutralisation, glucagon receptor antagonism, nor alpha cell removal, but did not deteriorate further compared with mice with intact alpha cell mass. CONCLUSIONS/
INTERPRETATION: Disruption of glucagon action/secretion did not improve glucose tolerance in diabetic mice. Near-total alpha cell elimination may have prevented further deterioration. Our findings support insulin lack as the major factor underlying hyperglycaemia in beta cell-deficient diabetes.

Entities:  

Keywords:  Endocrine pancreas; Glucagon; Glucose homeostasis; Streptozotocin; Type 1 diabetes

Mesh:

Substances:

Year:  2015        PMID: 26537124     DOI: 10.1007/s00125-015-3794-2

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  23 in total

1.  Metabolic manifestations of insulin deficiency do not occur without glucagon action.

Authors:  Young Lee; Eric D Berglund; May-yun Wang; Xiaorong Fu; Xinxin Yu; Maureen J Charron; Shawn C Burgess; Roger H Unger
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-13       Impact factor: 11.205

2.  Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis.

Authors:  Safina Ali; Benjamin J Lamont; Maureen J Charron; Daniel J Drucker
Journal:  J Clin Invest       Date:  2011-04-11       Impact factor: 14.808

3.  Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway.

Authors:  May-Yun Wang; Hai Yan; Zhiqing Shi; Matthew R Evans; Xinxin Yu; Young Lee; Shiuhwei Chen; Annie Williams; Jacques Philippe; Michael G Roth; Roger H Unger
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-09       Impact factor: 11.205

Review 4.  Biology of incretins: GLP-1 and GIP.

Authors:  Laurie L Baggio; Daniel J Drucker
Journal:  Gastroenterology       Date:  2007-05       Impact factor: 22.682

5.  Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor.

Authors:  János T Kodra; Anker Steen Jørgensen; Birgitte Andersen; Carsten Behrens; Christian Lehn Brand; Inger Thøger Christensen; Mette Guldbrandt; Claus Bekker Jeppesen; Lotte B Knudsen; Peter Madsen; Erica Nishimura; Christian Sams; Ulla G Sidelmann; Raymon A Pedersen; Francis C Lynn; Jesper Lau
Journal:  J Med Chem       Date:  2008-08-16       Impact factor: 7.446

6.  Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice.

Authors:  R W Gelling; X Q Du; D S Dichmann; J Romer; H Huang; L Cui; S Obici; B Tang; J J Holst; C Fledelius; P B Johansen; L Rossetti; L A Jelicks; P Serup; E Nishimura; M J Charron
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-24       Impact factor: 11.205

7.  Stimulation of hepatic glycogen synthesis by amino acids.

Authors:  J Katz; S Golden; P A Wals
Journal:  Proc Natl Acad Sci U S A       Date:  1976-10       Impact factor: 11.205

8.  Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs.

Authors:  F G Baldissera; J J Holst; S Knuhtsen; L Hilsted; O V Nielsen
Journal:  Regul Pept       Date:  1988-05

9.  Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes.

Authors:  R P Kelly; P Garhyan; E Raddad; H Fu; C N Lim; M J Prince; J A Pinaire; M T Loh; M A Deeg
Journal:  Diabetes Obes Metab       Date:  2015-03-02       Impact factor: 6.408

10.  Normal glucagon signaling and β-cell function after near-total α-cell ablation in adult mice.

Authors:  Fabrizio Thorel; Nicolas Damond; Simona Chera; Andreas Wiederkehr; Bernard Thorens; Paolo Meda; Claes B Wollheim; Pedro L Herrera
Journal:  Diabetes       Date:  2011-09-16       Impact factor: 9.461

View more
  19 in total

Review 1.  A synopsis of factors regulating beta cell development and beta cell mass.

Authors:  Krishna Prasadan; Chiyo Shiota; Xiao Xiangwei; David Ricks; Joseph Fusco; George Gittes
Journal:  Cell Mol Life Sci       Date:  2016-04-22       Impact factor: 9.261

Review 2.  Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?

Authors:  Magnus F Grøndahl; Damien J Keating; Tina Vilsbøll; Filip K Knop
Journal:  Curr Diab Rep       Date:  2017-10-28       Impact factor: 4.810

3.  Hypoglycemic Effect of Combined Ghrelin and Glucagon Receptor Blockade.

Authors:  Bharath K Mani; Aki Uchida; Young Lee; Sherri Osborne-Lawrence; Maureen J Charron; Roger H Unger; Eric D Berglund; Jeffrey M Zigman
Journal:  Diabetes       Date:  2017-05-09       Impact factor: 9.461

4.  Glucagon receptor inhibition normalizes blood glucose in severe insulin-resistant mice.

Authors:  Haruka Okamoto; Katie Cavino; Erqian Na; Elizabeth Krumm; Sun Y Kim; Xiping Cheng; Andrew J Murphy; George D Yancopoulos; Jesper Gromada
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-23       Impact factor: 11.205

5.  Reduced islet function contributes to impaired glucose homeostasis in fructose-fed mice.

Authors:  Zeenat A Asghar; Andrew Cusumano; Zihan Yan; Maria S Remedi; Kelle H Moley
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-12-27       Impact factor: 4.310

6.  Disruption of glucagon receptor signaling causes hyperaminoacidemia exposing a possible liver-alpha-cell axis.

Authors:  Katrine D Galsgaard; Marie Winther-Sørensen; Cathrine Ørskov; Hannelouise Kissow; Steen S Poulsen; Hendrik Vilstrup; Cornelia Prehn; Jerzy Adamski; Sara L Jepsen; Bolette Hartmann; Jenna Hunt; Maureen J Charron; Jens Pedersen; Nicolai J Wewer Albrechtsen; Jens J Holst
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-10-03       Impact factor: 4.310

7.  Endogenous GIP ameliorates impairment of insulin secretion in proglucagon-deficient mice under moderate beta cell damage induced by streptozotocin.

Authors:  Atsushi Iida; Yusuke Seino; Ayako Fukami; Ryuya Maekawa; Daisuke Yabe; Shinobu Shimizu; Keita Kinoshita; Yusuke Takagi; Takako Izumoto; Hidetada Ogata; Kota Ishikawa; Nobuaki Ozaki; Shin Tsunekawa; Yoji Hamada; Yutaka Oiso; Hiroshi Arima; Yoshitaka Hayashi
Journal:  Diabetologia       Date:  2016-04-06       Impact factor: 10.122

8.  Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist.

Authors:  Nicolas Damond; Fabrizio Thorel; Julie S Moyers; Maureen J Charron; Patricia M Vuguin; Alvin C Powers; Pedro L Herrera
Journal:  Elife       Date:  2016-04-19       Impact factor: 8.140

9.  Partners for life.

Authors:  Lena Eliasson; Anna Wendt
Journal:  Elife       Date:  2016-05-18       Impact factor: 8.140

Review 10.  Glucose control of glucagon secretion-'There's a brand-new gimmick every year'.

Authors:  Erik Gylfe
Journal:  Ups J Med Sci       Date:  2016-04-04       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.